Brief: Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
15/03/2024 12:29
March 15 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS: NASDAQ PANEL GRANTED REQUEST FOR
EXTENSION
TO EVIDENCE COMPLIANCE WITH ALL APPLICABLE CRITERIA FOR
CONTINUED LISTING ON NASDAQ
* AVENUE THERAPEUTICS INC: NASDAQ GRANTED EXTENSION THROUGH
MAY
20, 2024
Source text for Eikon: ID:nGNX75hmDW
Further company coverage: ATXI.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary